Drugs / XmAb7195
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02881853 | Aug 2016 → Feb 2017 | atopic IgE-mediated allergic disorder | Xencor, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02148744 | May 2014 → Sep 2015 | allergic rhinitis, atopic eczema, conjunctivitis | Xencor, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2017-11-07 | Xencor, Inc. | Results Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update xencor.com ↗
Today, we are pleased to announce data from our Phase 1b trial of subcutaneously administered XmAb7195, which shows potent IgE reduction with improved tolerability compared to intravenous administration, and supports subcutaneous administration in future development. |
| 2016-06-28 | Xencor, Inc. | Results Xencor Provides Updates on Lead Programs and Reviews Bispecific Oncology Partnership; Announces Expansion of Bispecific Oncology Pipeline at Analyst Day xencor.com ↗
Today, Xencor will discuss the recently presented data from the Phase 1a study of XmAb7195 showing that XmAb7195 was generally well tolerated and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. |
| 2016-05-18 | Xencor, Inc. | Results Xencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing Rapid Reduction of Serum IgE in High IgE Atopic Subjects at ATS 2016 International Conference xencor.com ↗
Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. |
| 2015-01-29 | Xencor, Inc. | Results Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers xencor.com ↗
The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. |
| 2014-05-15 | Xencor, Inc. | Results Xencor Presents Study Comparing XmAb7195 to Omalizumab at the American Thoracic Society 2014 International Conference xencor.com ↗
The study describes XmAb7195's three distinct mechanisms of action, including a novel mechanism for rapid clearance of IgE. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb7195 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02881853 ↗ |
| Route | Intravenous | “Single IV infusion of XmAb7195 or placebo” NCT02148744 ↗ |